Figure 2From: Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis Forest plots from a sensitivity analysis of overall survival (A) and disease-free survival (B) for the adjuvant use of zoledronic acid compared to the control arm, with a median follow-up period of 5 years. Back to article page